Unbxd vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Jose AI product discovery platform founded 2012; raised $15M+; replaces native ecommerce search with behavior-learning AI for enterprise and mid-market retailers across US and India.
About
Unbxd was founded in 2012 in San Jose, California and raised over $15M to build an AI-powered product discovery platform for e-commerce, with a focus on enterprise and mid-market retailers in the US and India. The company's platform replaces platform-native search and category navigation with AI-driven product discovery that learns from shopper behavior, improves result relevance over time, and provides merchandisers with tools to control and optimize the shopping experience.\n\nUnbxd covers site search, category browse, product recommendations, and an analytics suite that helps merchandising and digital teams understand how shoppers interact with discovery features and where revenue is being lost. The platform's merchandising console allows e-commerce teams to set up boost and bury rules, create search landing pages, manage synonyms, and configure redirect rules without engineering involvement, which is a requirement for most retail merchandising teams that operate on fast-moving promotional calendars.\n\nUnbxd has a notable presence in the Indian e-commerce market alongside its North American customer base, serving large retailers and marketplace operators in both regions. The company competes against Klevu, Searchspring, and Netcore in the product discovery space, differentiating through its strong presence in the Indian market and its combined approach of AI relevance and merchandiser control tools.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.